Literature DB >> 28990593

Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression.

Marian T Sepulveda-Orengo1, Kati L Healey1, Ronald Kim1, Alyson C Auriemma1, Jennifer Rojas1, Nicholas Woronoff1, Rachel Hyppolite1, Kathryn J Reissner1,2.   

Abstract

Adaptations in glutamate signaling within the brain's reward circuitry are observed following withdrawal from several abused drugs, including cocaine. These include changes in intrinsic cellular excitability, glutamate release, and glutamate uptake. Pharmacological or optogenetic reversal of these adaptations have been shown to reduce measures of cocaine craving and seeking, raising the hypothesis that regulation of glutamatergic signaling represents a viable target for the treatment of substance use disorders. Here, we tested the hypothesis that administration of the compound riluzole, which regulates glutamate dynamics in several ways, would reduce cocaine seeking in the rat self-administration and reinstatement model of addiction. Riluzole dose-dependently inhibited cue- and cocaine-primed reinstatement to cocaine, but did not affect locomotor activity or reinstatement to sucrose seeking. Moreover, riluzole reversed bidirectional cocaine-induced adaptations in intrinsic excitability of prelimbic (PL) and infralimbic (IL) pyramidal neurons; a cocaine-induced increase in PL excitability was decreased by riluzole, and a cocaine-induced decrease in IL excitability was increased to normal levels. Riluzole also reversed the cocaine-induced suppression of the high-affinity glutamate transporter 1 (EAAT2/GLT-1) in the nucleus accumbens (NAc). GLT-1 is responsible for the majority of glutamate uptake in the brain, and has been previously reported to be downregulated by cocaine. These results demonstrate that riluzole impairs cocaine reinstatement while rectifying several cellular adaptations in glutamatergic signaling within the brain's reward circuitry, and support the hypothesis that regulators of glutamate homeostasis represent viable candidates for pharmacotherapeutic treatment of psychostimulant relapse.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28990593      PMCID: PMC5916346          DOI: 10.1038/npp.2017.244

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  68 in total

1.  Physiological role of calcium-activated potassium currents in the rat lateral amygdala.

Authors:  E S Louise Faber; Pankaj Sah
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

Review 2.  Calcium-activated potassium channels: multiple contributions to neuronal function.

Authors:  E S Louise Faber; Pankaj Sah
Journal:  Neuroscientist       Date:  2003-06       Impact factor: 7.519

Review 3.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

4.  Repeated cocaine administration increases voltage-sensitive calcium currents in response to membrane depolarization in medial prefrontal cortex pyramidal neurons.

Authors:  Fernando J Nasif; Xiu-Ti Hu; Francis J White
Journal:  J Neurosci       Date:  2005-04-06       Impact factor: 6.167

5.  Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.

Authors:  Alice Y C Liu; Rohan Mathur; Newton Mei; Christopher G Langhammer; Bruce Babiarz; Bonnie L Firestein
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

Review 6.  Glutamate transporters: confining runaway excitation by shaping synaptic transmission.

Authors:  Anastassios V Tzingounis; Jacques I Wadiche
Journal:  Nat Rev Neurosci       Date:  2007-12       Impact factor: 34.870

7.  The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.

Authors:  F Duprat; F Lesage; A J Patel; M Fink; G Romey; M Lazdunski
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

Review 8.  Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.

Authors:  Douglas J Roberts-Wolfe; Peter W Kalivas
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

9.  Learning and aging related changes in intrinsic neuronal excitability.

Authors:  M Matthew Oh; Fernando A Oliveira; John F Disterhoft
Journal:  Front Aging Neurosci       Date:  2010-02-03       Impact factor: 5.750

10.  Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.

Authors:  Elena Fumagalli; Marcella Funicello; Thomas Rauen; Marco Gobbi; Tiziana Mennini
Journal:  Eur J Pharmacol       Date:  2007-10-25       Impact factor: 4.432

View more
  12 in total

1.  Impact of Acute and Persistent Excitation of Prelimbic Pyramidal Neurons on Motor Activity and Trace Fear Learning.

Authors:  Timothy R Rose; Ezequiel Marron Fernandez de Velasco; Baovi N Vo; Megan E Tipps; Kevin Wickman
Journal:  J Neurosci       Date:  2021-01-05       Impact factor: 6.167

2.  Reversing Cocaine-Induced Adaptations and Reducing Relapse: An Opportunity for Repurposing Riluzole.

Authors:  Joseph J Ziminski; Eisuke Koya
Journal:  Neuropsychopharmacology       Date:  2018-01-17       Impact factor: 7.853

3.  Biphasic effect of abstinence duration following cocaine self-administration on spine morphology and plasticity-related proteins in prelimbic cortical neurons projecting to the nucleus accumbens core.

Authors:  B M Siemsen; G Giannotti; J A McFaddin; M D Scofield; Jacqueline F McGinty
Journal:  Brain Struct Funct       Date:  2018-11-29       Impact factor: 3.270

4.  Elevation of Extracellular Glutamate by Blockade of Astrocyte Glutamate Transporters Inhibits Cocaine Reinforcement in Rats via a NMDA-GluN2B Receptor Mechanism.

Authors:  Hong-Ju Yang; Briana J Hempel; Guo-Hua Bi; Yi He; Hai-Ying Zhang; Eliot L Gardner; Zheng-Xiong Xi
Journal:  J Neurosci       Date:  2022-01-28       Impact factor: 6.709

Review 5.  Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders.

Authors:  Gigliola Marrero-Cristobal; Ursula Gelpi-Dominguez; Roberto Morales-Silva; John Alvarado-Torres; Joshua Perez-Torres; Yobet Perez-Perez; Marian Sepulveda-Orengo
Journal:  J Neurosci Res       Date:  2021-12-01       Impact factor: 4.433

6.  A sex-dependent role for the prelimbic cortex in impulsive action both before and following early cocaine abstinence.

Authors:  Travis M Moschak; Regina M Carelli
Journal:  Neuropsychopharmacology       Date:  2021-05-10       Impact factor: 8.294

7.  MC-100093, a Novel β-Lactam Glutamate Transporter-1 Enhancer Devoid of Antimicrobial Properties, Attenuates Cocaine Relapse in Rats.

Authors:  Lori A Knackstedt; Lizhen Wu; Jeffrey Rothstein; Svetlana Vidensky; John Gordon; Mercy Ramanjulu; Paul Dunman; Benjamin Blass; Wayne Childers; Magid Abou-Gharbia
Journal:  J Pharmacol Exp Ther       Date:  2021-05-13       Impact factor: 4.402

8.  Sequential cocaine-alcohol self-administration produces adaptations in rat nucleus accumbens core glutamate homeostasis that are distinct from those produced by cocaine self-administration alone.

Authors:  Bethany A Stennett; Yasmin Padovan-Hernandez; Lori A Knackstedt
Journal:  Neuropsychopharmacology       Date:  2019-07-02       Impact factor: 8.294

Review 9.  Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits.

Authors:  Manoranjan S D'Souza
Journal:  Front Psychiatry       Date:  2019-07-24       Impact factor: 4.157

10.  Prefrontal Neuronal Excitability Maintains Cocaine-Associated Memory During Retrieval.

Authors:  James M Otis; Michael K Fitzgerald; Hanna Yousuf; Jake L Burkard; Matthew Drake; Devin Mueller
Journal:  Front Behav Neurosci       Date:  2018-06-14       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.